Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen

Guymer, Robyn H.; Markey, Caroline M.; McAllister, Ian L.; Gillies, Mark C.; Hunyor, Alex P.; Arnold, Jennifer J.; Chang, Andrew; Syed, Adil; Broadhead, Geoffrey; Pham, Thomas; Hong, Thomas; Wong, Lily; Zhu, Meidong; Burnett, Shelley; Joachim, Nichole; Wijeyakumar, Wijeyanthy; Manalang, Gabriel; Mhlanga, Cleopatra; Joachim, Nicole; Spooner, Kimperly; Mitchell, Paul; Foran, Suriya; Wilson, Christabel; Cossatto, Victoria; Waniganayke, Laskshmi; Mai, Vivien; Atif, Rabiya; Wa, Lakshmi; Maharaj, Sapna; Liong, David; Matic, Christine; Maharaj, Sapna; Tran, Katherine; Jas, Sheenal; Gibbs, Danielle; Wickremasinghe, Sanj; Guymer, Robyn; Lim, Lyndell; Sandhu, Sukhpal; Nguyen, Thanh; Qatarneh, Dania; Razavi, Hessom; Chong, Elaine; Little, Matthew; Bhardwau, Gaurav; Ayres, Michael; Chen, Michael; Ong, Daini; Creese, Katarina; Drew, Tricia

doi:10.1016/j.ophtha.2018.11.025

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen

PURPOSE To test the hypothesis that tolerating some subretinal fluid (SRF) in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab using a treat-and-extend (T&E) regimen can achieve similar visual acuity (VA) outcomes as treatment aimed at resolving all SRF. …